Methods for producing microRNAs

Details Methods for producing microRNAs Methods for producing microRNAs

2011-08-09

2011-08-09

Schnizer, Richard (Department: 1635)

Chemistry: molecular biology and microbiology

Process of mutation, cell fusion, or genetic modification

Introduction of a polynucleotide molecule into or...

C435S456000, C435S457000, C435S458000, C536S024500, C800S021000, C800S023000

Reexamination Certificate

active

07993925

ABSTRACT:
The invention relates to recombinant vectors for inducible and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene. In certain embodiments, the invention relates to the use of Tet (tetracycline)-responsive RNA Polymerase II (Pol II) promoters (e.g., TetON or TetOFF) to direct inducible knockdown in certain cells of an integrated or an endogenous gene, such as p53. The invention also relates to a method for producing transgenic animals (e.g., mice) expressing inducible (such as tetracycline-regulated), reversible, and/or tissue-specific double-stranded RNA molecules that interfere with the expression of a target gene.

REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 5593676 (1997-01-01), Bhat et al.
patent: 5672485 (1997-09-01), Foster et al.
patent: 5686072 (1997-11-01), Uhr et al.
patent: 5928638 (1999-07-01), Uchida et al.
patent: 6111093 (2000-08-01), Seed et al.
patent: 6134982 (2000-10-01), Takabatake et al.
patent: 6165737 (2000-12-01), Wang et al.
patent: 6306393 (2001-10-01), Goldenberg
patent: 6583333 (2003-06-01), Lowe et al.
patent: 2002/0041847 (2002-04-01), Goldenberg
patent: 2002/0086356 (2002-07-01), Tuschl et al.
patent: 2002/0132346 (2002-09-01), Cibelli
patent: 2002/0155604 (2002-10-01), Ledbetter et al.
patent: 2003/0148409 (2003-08-01), Rossi et al.
patent: 2003/0226159 (2003-12-01), Bachoo et al.
patent: 2004/0006035 (2004-01-01), Macejak et al.
patent: 2004/0039010 (2004-02-01), Grupp et al.
patent: 2004/0045043 (2004-03-01), Finney et al.
patent: 2004/0053411 (2004-03-01), Cullen et al.
patent: 2004/0053869 (2004-03-01), Andrews et al.
patent: 2004/0202658 (2004-10-01), Benyunes
patent: 2005/0003541 (2005-01-01), Katsuki et al.
patent: 2005/0070693 (2005-03-01), Hansen et al.
patent: 2005/0075492 (2005-04-01), Chen et al.
patent: 2005/0143448 (2005-06-01), Grenard et al.
patent: 2005/0191302 (2005-09-01), Arthur et al.
patent: 2005/0233391 (2005-10-01), Spies et al.
patent: 2006/0040391 (2006-02-01), Bailey et al.
patent: 2006/0123494 (2006-06-01), Wu et al.
patent: 2006/0135456 (2006-06-01), Hannon et al.
patent: 2006/0162000 (2006-07-01), Zender et al.
patent: 2006/0240556 (2006-10-01), Cibelli
patent: 2006/0247193 (2006-11-01), Taira et al.
patent: 2006/0286584 (2006-12-01), Duojia
patent: 2006/0294604 (2006-12-01), Fridman et al.
patent: 2007/0033663 (2007-02-01), Katsuki et al.
patent: 2007/0044164 (2007-02-01), Dickins et al.
patent: 2007/0078084 (2007-04-01), Kishore et al.
patent: 2007/0178106 (2007-08-01), Romagne
patent: 2008/0025958 (2008-01-01), Hannon et al.
patent: 2008/0226553 (2008-09-01), Lowe et al.
patent: 2008/0242622 (2008-10-01), Lowe et al.
patent: 2009/0022685 (2009-01-01), Lowe et al.
patent: 2009/0029872 (2009-01-01), Zender et al.
patent: 2009/0082298 (2009-03-01), Dickins et al.
patent: 2009/0186839 (2009-07-01), Lowe et al.
patent: 1092783 (2001-04-01), None
patent: 1247865 (2005-06-01), None
patent: WO-91/13974 (1991-09-01), None
patent: WO-94/09363 (1994-04-01), None
patent: WO-95/03770 (1995-02-01), None
patent: WO-96/36360 (1996-11-01), None
patent: WO-99/32619 (1999-07-01), None
patent: WO-99/55886 (1999-11-01), None
patent: WO-00/20025 (2000-04-01), None
patent: WO-00/67796 (2000-11-01), None
patent: WO-01/13945 (2001-03-01), None
patent: WO-01/36646 (2001-05-01), None
patent: WO-01/68836 (2001-09-01), None
patent: WO-02/16620 (2002-02-01), None
patent: WO-02/50118 (2002-06-01), None
patent: WO-02/072762 (2002-09-01), None
patent: WO-03/042382 (2003-05-01), None
patent: WO 03/093441 (2003-11-01), None
patent: WO-2004/022722 (2004-03-01), None
patent: WO-2004/029219 (2004-04-01), None
patent: WO-2004035782 (2004-04-01), None
patent: WO-2004/074445 (2004-09-01), None
patent: WO-2005/012493 (2005-02-01), None
patent: WO-2005/013886 (2005-02-01), None
patent: WO-2005/017148 (2005-02-01), None
patent: WO-2005/020969 (2005-03-01), None
patent: WO-2006023848 (2006-03-01), None
patent: WO-2006/074186 (2006-07-01), None
patent: WO-2007/053184 (2007-05-01), None
patent: WO-2007/139985 (2007-12-01), None
patent: WO-2008/115556 (2008-09-01), None
patent: WO-2008/124133 (2008-10-01), None
patent: WO-2008/143979 (2008-11-01), None
patent: WO-2009/042798 (2009-04-01), None
patent: WO-2009/055724 (2009-04-01), None
Rabbani et al (Endocrinology 136(12): 5416-5422, 1995).
Grellier et al (Cancer Res. 58: 1670-1676, 1998).
Seibler et al (Nucl. Acids Res. 33(7): e67, published online Apr. 24, 2005).
Rubinson et al (Nature Genetics 33: 401-407, 2003).
Wang et al (Proc. Nat. Acad. Sci. USA 100(9): 5103-5106, 2003).
Griffin et al ( Cancer Res. 64: 8811-8815, 2004).
Lottmann et al (J. Mol. Med 79: 321-328, 2001).
Fux et al (Nucl. Acids Res. 29(4) : e19, 2001).
Dickins et al., “Probing Tumor Phenitypes Using Stable and Regulated Synthetic MicroRNA Precursors,” Nature Genetics, 37(11):1289-1295 (2005).
Tavernarakis et al., “Heritable and Inducible Genetic Interference by double-Stranded RNA Encoded by Transgenes,” Nature Genetics, 24:180-183 (2000).
Zeng et al., Use of RNA Polymerase II to Transcribe artificial MicroRNAS, Methods in Enzymology, 392:371-380 (2005).
U.S. Appl. No. 12/617,624, Zender et al.
U.S. Appl. No. 12/600,427, Bric et al.
Aas,T., et al, (1996). Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 2,811-814.
Adams, et al.., “The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice” Nature, 318 (1985) pp. 533-538.
Agrawal et al., Mol Med Today. Feb. 2000;6(2):72-81 Antisense therapeutics: is it as simple as complementary base recognition?
Akimitsu, N. et al. (2003) Enforced cytokinesis without complete nuclear division in embryonic cells depletinQ the activity of DNA topoisDmerase IIa. Genes to Cells 8, 393-402.
Alison & Lovell, “Liver cancer: the role of stem cells.” Cell Prolif. vol. 38, pp. 407-421 (2005).
Anderson, Human gene therapy, (Nature 392:25-30, 1998).
Andjelkovic, et al., “Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors”Proc. Natl. Acad. Sci. USA, 93, (1996) pp. 5699-5704.
Andjelkovic, et al., “Role of translocation in the activation and function of protein kinase B,”J. Biol. Chem, 272, (1997) pp. 31515-31524.
Andoh,T. and Ishida,R. (1998). Catalytic inhibitors of DNA topoisomerase II. Biochim. Biophys. Acta 1400,155-171.
Aoki, et al., “The Akt kinase: Molecular determinants of oncogenicity.” Proc. Natl. Acad. Csi.; vol. 95, pp. 14950-14955 (1998).
Arriola,E., et al., (2006). Predictive value of HER-2 and Topoisomerase IIalpha in response to primary doxorubicin in breast cancer. Eur. J. Cancer 42, 2954-2960.
Bartz et al., “Small interfering RNA Screens Reveal Enhanced Cisplatin Cytotoxicity in Tumor Cells having both BRCA Network and TP53 Disruptions,” Mol. Cell. Biol., vol. 26, pp. 9377-9386 (Dec. 2006).
Bashyam et al., “Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer,” Neoplasia 7, pp. 556-562 (2005).
Basu et al., “Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis,” Mol Cell 11, 11-23 (2003).
Baulcombe, Gene silencing: RNA make RNA makes no protein, 1999, Curr. Biol. 9:R599-R601.
Beard et al., “Efficient Method to Generate Single-Copy Transgenic Mice by Site-Specific Integration in Embyonic Stem Cells,” Genesis, vol. 44: pp. 23-28 (2006).
Bern et al., A Functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer, Cancer Cell, vol. 12, pp. 395-402, (2007).
Billy, et al., “Specific interference with gene expression induced by long, double-stranded RNA in mouse embryonal teratocarcinoma cell lines,” PNAS, 98(25):14428-14433 (2001).
Berns et a

Affiliated with

Also associated with

Rating

Methods for producing microRNAs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for producing microRNAs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for producing microRNAs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2635630